लोड हो रहा है...

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Med
मुख्य लेखकों: Solitano, Virginia, D’Amico, Ferdinando, Fiorino, Gionata, Paridaens, Kristine, Peyrin-Biroulet, Laurent, Danese, Silvio
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: MDPI 2020
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/
https://ncbi.nlm.nih.gov/pubmed/32911840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!